In an analysis of all FDA approvals for anticancer drugs from 2009 to 2020, only about 29% of next-in-class drugs were evaluated in head-to-head randomized clinical trials (RCTs) against their ...

Pretreatment with EZH2 inhibitor (top right) leads to higher recruitment of CAR-T cells (red) into the lymph node tumor compared with control (top left). Pretreatment with EZH2 inhibitor (bottom right ...

Identifying the mechanisms of action driving a drug’s anti-cancer efficacy is critical for identifying optimal biomarkers, indications, and combinations for clinical success. Yet, systematically ...

Schematic model of the excretion of incorporated anticancer drugs from ABCB1 via the activation of TAS2Rs. Various anticancer drugs are incorporated into cancer cells, followed by severe cell damage ...